Regeneron And Sanofi's Dupixent Becomes First Biologic To Achieve Significant Improvements In Disease Remission In Bullous Pemphigoid Trial
Regeneron And Sanofi's Dupixent Becomes First Biologic To Achieve Significant Improvements In Disease Remission In Bullous Pemphigoid Trial
Regeneron和赛诺菲安万特的Dupixent成为首个在大疱性天疱疮试验中取得显著疗效改善的生物制剂。
- Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
- Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease
- If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union
- 该试验符合成人中度至重度疾病的主要和所有关键次要终点；使用Dupixent实现持续缓解的患者是安慰剂的五倍
- Dupixent是第一种对这种使人衰弱和危及生命的疾病显示出显著的类固醇保护作用的药物
- 如果获得批准，Dupixent将成为美国和欧盟第一种也是唯一一种治疗血压的靶向药物